Skip to main content
. 2017 Sep 29;23(11):866–874. doi: 10.1111/cns.12759

Table 1.

Baseline characteristics of patients and cellular treatment administered (n = 10)

Mean (±SD) Range
(A)
Age (Y) 34.9 (±9.54) (18; 54)
MS duration (Y) 9.6 (±2.91) (4; 15)
Post ‐treatments n %
Interferon b‐1 4 40
Interferon MXT 4 40
Interferon Nat 1 10
Interferon &SC 1 10
Mean (±SD) Range
(B)
Number of MSCs injected (×106) 110 (±23.1) (93; 168)
CM volume (mL) 18.3 (±2.79) (13; 20)

MXT, Mitoxantrone; Nat, Natalizumab; SC, stem cell; MSCs, mesenchymal stem cells; CM, conditioned media.